Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
enGene
Biotech
EnGene cancer sales forecast cut after new data widen gap to J&J
Leerink analysts slashed their forecast for enGene’s bladder cancer candidate after phase 2 data dented their belief that the biotech can match J&J.
Nick Paul Taylor
May 8, 2026 9:08am
GSK chief steps down in stunning move—Chutes & Ladders
Oct 3, 2025 8:30am
Protara gears up for next commercial steps—Chutes & Ladders
Jun 6, 2025 8:30am
Moderna, Terremoto, MEI Pharma and more—Chutes & Ladders
Jul 26, 2024 8:30am
enGene drops cystic fibrosis program to focus on bladder cancer
Jun 14, 2024 8:20am
FDA promotes Bumpus to replace Woodcock—Chutes & Ladders
Dec 1, 2023 9:48am
